Ascendis Pharma (ASND) said late Wednesday its board has allocated $25 million to fund a share buyback program and the net settlement of certain restricted stock units, or RSUs.
The buyback program authorizes the repurchase from time to time of up to about $18.3 million of American depositary shares.
The company also plans to apply a net settlement of tax-withholding obligations related to certain RSUs for about $9 million in cash.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。